- Home
- Equipment
- usa california
- hematology malignancies
Refine by
Hematology Malignancies Equipment Supplied In Usa California
11 equipment items found
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, colorectal, endometrial, prostate, pancreatic) and others (renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid tumors. ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
Many hematologic malignancies carry characteristic chromosomal translocations believed to play an important role in the pathogenesis of these tumors. Chromosomal translocations found in leukemias and lymphomas either fuse enhancer/promoter regions of one gene to another, causing aberrant expression, or by fusing a part of one gene to that of another, resulting in ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...
Manufactured by:Targazyme, Inc. based inCarlsbad, CALIFORNIA (USA)
TZ 102, like all of TargaZyme’s therapeutics, is an off-the-shelf product for point-of-care use. It’s made of two (2) components, fucosyltransferase VII enzyme and GDP ...